Respien Appoints Sage to Lead Global Partnering Process for HI-164, a Phase 3-Ready COPD Therapy
HI-164 is available for partnering: a late-stage oral therapy designed to reduce bacterial exacerbations, hospital admissions and the healthcare burden of COPD. CAMBRIDGE, UNITED KINGDOM, June 8, 2026 /EINPresswire.com/ -- Respien Pty Ltd (“ …